Report and Unaudited Financial Statements

Year Ended

31 December 2010

Company Number 1136169

FRIDAY

AAP2HXZI*

A18

30/09/2011 COMPANIES HOUSE 325

Report and financial statements for the year ended 31 December 2010

Contents

Page:

- 1 Report of the directors
- 2 Balance sheet
- 3 Notes forming part of the financial statements

Directors

BBI Enzymes Limited Adam Biotechnology Limited L Rees

Registered office

Berry Smith LLP, Haywood House, Dumfries Place, Cardiff, CF10 3GA

Company number

1136169

Report of the directors for the year ended 31 December 2010

The directors present their report together with the financial statements for the year ended 31 December 2010

Results

The company has been dormant for the entire year

Directors

The directors of the company during the year were

BBI Enzymes Limited Adam Biotechnology Limited C Anderson (Resigned 30 April 2010) L Rees (Appointed 22 April 2010)

In preparing this directors' report advantage has been taken of the small companies' exemption

On behalf of the board

Laylor on behalf of BBI Enzymes Limited

Director

Date September 2011

30 h

Balance sheet at 31 December 2010

· 		- · · · · · · · · · · · · · · · · · · ·	
Company number 1136169	Note	2010 £'000	2009 £'000
		-	_
Capital and reserves Called up share capital Share premium account Capital redemption reserve Profit and loss account	3	18 689 7 (714)	18 689 7 (714)
Shareholders' funds		-	-

For the year ended 31 December 2010 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006

Members have not required the Company to obtain an audit in accordance with section 476 of the Companies Act 2006

The directors acknowledge their responsibilities for complying

- ensuring the company keeps accounting records which comply with section 386 of the Companies Act 2006
- preparing financial statements which give a true and fair view of the state of affairs of the Company as at the end of the financial year and of its profit or loss for the financial year, in accordance with the requirements of section 394 and 395 of the Act and which otherwise comply with the requirements of the Companies Act 2006 relating to accounts, so far as applicable to the Company

The financial statements were approved by the board of directors and authorised for issue on September 2011

L Taylor on behalf of BBI Enzymes Limited Director

The notes on pages 3 to 4 form part of these financial statements

Notes forming part of the financial statements for the year ended 31 December 2010

1 Accounting policies

The financial statements have been prepared under the historical cost convention and in accordance with the Companies Act 2006 and applicable accounting standards in the United Kingdom

Consolidated financial statements

The financial statements contain information about F&H Baxter (Holdings) Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company has taken advantage of the exemption conferred by section 400 of the Companies Act 2006 not to produce consolidated financial statements as it is included in the consolidated financial statements of BBI Holdings Limited which are publicly available.

2 Fixed asset investments

3

	Group undertakings £'000
Cost At 1 January 2010 and 31 December 2010	926
Provisions At 1 January 2010 and 31 December 2010	926
Net book value At 31 December 2009 and 31 December 2010	—

Subsidiary undertakings, associated undertakings and other investments

The principal undertakings in which the company's interest at the year end is 20% or more are as follows

	Country of incorporation or registration	Class of share capital held	Proportion of share capital held	Nature of	business
Cambridge Bio-Nutritional Limited	England and Wales	Ordinary	100%	Dental distribution industry	
Share capital					
				2010 £'000	2009 £'000
Allotted, called up and fully paid					
17,660 (2009 17,660) ordinary shares o	f £1 each			18	18

Notes forming part of the financial statements for the year ended 31 December 2010 (continued)

4 Ultimate holding company and controlling party

The immediate parent undertaking is BBI Enzymes Limited, which is incorporated in England and Wales BBI Enzymes Limited is owned and controlled by BBI Holdings Limited which is incorporated in England and Wales. The ultimate parent company is Alere Inc., which is incorporated in the United States of America and is the ultimate controlling party.

At the balance sheet date, BBI Holdings Limited is the smallest company which prepares consolidated financial statements. Copies of the financial statements are available from Companies House

Alere Inc , is the largest company in the group which prepares consolidated financial statements